Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Free Cash Flow (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Free Cash Flow for 14 consecutive years, with -$18.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 33.56% year-over-year to -$18.6 million, compared with a TTM value of -$106.1 million through Dec 2025, up 13.76%, and an annual FY2025 reading of -$106.1 million, up 13.76% over the prior year.
  • Free Cash Flow was -$18.6 million for Q4 2025 at Fate Therapeutics, up from -$26.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$18.6 million in Q4 2025 and bottomed at -$74.5 million in Q4 2022.
  • Average Free Cash Flow over 5 years is -$39.2 million, with a median of -$32.9 million recorded in 2024.
  • The sharpest move saw Free Cash Flow plummeted 174.39% in 2021, then soared 52.83% in 2023.
  • Year by year, Free Cash Flow stood at -$42.3 million in 2021, then crashed by 75.9% to -$74.5 million in 2022, then surged by 42.76% to -$42.6 million in 2023, then skyrocketed by 34.49% to -$27.9 million in 2024, then surged by 33.56% to -$18.6 million in 2025.
  • Business Quant data shows Free Cash Flow for FATE at -$18.6 million in Q4 2025, -$26.6 million in Q3 2025, and -$25.9 million in Q2 2025.